References
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–1205
- Ives TJ, Bentz EJ, Gwyther RE. Dermatologic adverse drug reactions in a family medicine setting. Arch Fam Med 1992;1:241–245
- Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922;24:526–533
- Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355–361
- Roujeau JC, Sterns RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272–1285
- Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiform, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43–47
- Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600–1607
- Borchers A, Lee J, Naguwa S, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008;7:598–605
- Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens–Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97:272–280
- Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004;428:486
- Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens––Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087–2091
- Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134–4139
- Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study iden- tifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011;20:1034–1041
- McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134–1143
- Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010;51:2461–2465
- Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297–306
- Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349–356
- Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010;11:879–884
- Su S, Chung W. Update on pathobiology in Stevens–Johnson syndrome and toxic epidermal necrolysis. Dermatolog Sinic 2013;31:175–180
- Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241–253
- Ducic I, Shalom A, Rising W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002;110:768–773
- Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–153
- Lissia M, Mulas P, Bulla A, et al. Toxic epidermal necrolysis (Lyelĺs disease). Burns 2010;36:152–163
- Mukasa Y, Craven N. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J 2008;84:60–65
- Mahar P, Wasiak J, Hii B, et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres. Burns 2014;40:1245–1254
- Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology 2008;217:254–259